ELECTROPHYSIOLOGY TRANSFORMING ARTRIAL FIBRILLATION TREATMENT.

Millennium Research Group (MRG), Waltham, Mass., a global authority on medical technology market intelligence, has recently published its latest issue of Cardiovascular Industry Quarterly (CardioIQ), a quarterly publication highlighting the most recent trends and events in the cardiovascular industry.

According to CardioIQ, electrophysiology (EP) catheter ablation is emerging as the preferred treatment for atrial fibrillation (AF), a common form of cardiac arrhythmia that affects almost 3 million people in the US.

Technological innovation in EP catheter ablation, coupled with strong clinical outcomes, have resulted in increased physician recognition of EP catheter ablation as a viable option for treating AF patients, facilitating very rapid US procedure and market growth. Advances in EP catheter technology have enabled more accurate diagnoses and targeted therapies, while strong clinical outcomes have convinced physicians of the safety and efficacy of EP catheter ablation for AF treatment. The combination of increased physician recognition and benefits from innovative technological advancement will drive the market through 2012.

MRG also publishes quarterly publications on the orthopedics (OrthoIQ), aesthetics (AestheticsIQ), endoscopy, urology & gynecology (EndoIQ), and imaging and IT markets (ImagingIQ).

About Millennium Research Group

Millennium Research Group (http://www.mrg.net/), a Decision Resources, Inc. company (http://www.decisionresources.com/), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized consulting services.

For more information, visit http://www.mrg.net or call 416/364-7776, ext. 101.

Related Topics